メンバー紹介

原田　直純

教員名

原田　直純（はらだ　なおずみ） 特任講師

連絡先

〒514-8507 三重県津市江戸橋2-174
三重大学大学院 医学系研究科
遺伝子・免疫細胞治療学
電話： 059-231-5187
メール： nharada@clin.medic.mie-u.ac.jp

研究テーマ

がんワクチンの創薬研究。腫瘍免疫分野にフォーカスした分子標的薬の創薬研究。

プロフィール

神戸大学大学院医学研究科博士課程修了。製薬企業やベンチャーの研究所にて、10年間にわたりがん分子標的薬の探索研究に携わったのち、05年に当研究室に参加。がん免疫療法の研究開発、特にがんワクチンの有効性を高める新規設計技術の開発と非臨床研究に従事。 腫瘍免疫応答の抑制を解除する阻害剤の開発も進めている。趣味はフットサル・海釣り・絵画制作。

所属学会

日本癌学会、日本がん免疫学会

著作・論文

  1. Kashima H, Momose F, Umehara H, Miyoshi N, Ogo N, Muraoka D, Shiku H, Harada, N, Asai A. Epirubicin, Identified Using a Novel Luciferase Reporter Assay for Foxp3 Inhibitors, Inhibits Regulatory T Cell Activity. PLoS One. 2016 Jun 10;11(6):e0156643.
  2. Momose F, Seo N, Akahori Y, Sawada S, Harada N, Ogura T, Akiyoshi K, Shiku H. Guanine-Rich Sequences Are a Dominant Feature of Exosomal microRNAs across the Mammalian Species and Cell Types. PLoS One. 2016 Apr 21;11(4):e0154134.
  3. Sato YT, Umezaki K, Sawada S, Mukai SA, Sasaki Y, Harada N, Shiku H, Akiyoshi K. Engineering hybrid exosomes by membrane fusion with liposomes. Sci Rep. 2016 Feb 25;6:21933.
  4. Guidance Development Review Committee; Working Group for Clinical Studies of Cancer Immunotherapy; Working Group for Effector Cell Therapy; Working Group for CMC/Non-clinical Studies; Working Group for Cancer Vaccines and Adjuvants; Working Group for Anti-immune Checkpoint Therapy and Comprehensive Cancer Immunotherapy; Biostatistics Subcommittee. 2015 Guidance on cancer immunotherapy development in early-phase clinical studies. Cancer Sci. 2015 Dec;106(12):1761-71.
  5. Muraoka D, Harada N, Hayashi T, Tahara Y, Momose F, Sawada S, Mukai SA, Akiyoshi K, Shiku H. Nanogel-based immunologically stealth vaccine targets macrophages in the medulla of lymph node and induces potent antitumor immunity. ACS Nano. 2014 Sep 23;8(9):9209-18.
  6. Kageyama S, Wada H, Muro K, Niwa Y, Ueda S, Miyata H, Takiguchi S, Sugino SH, Miyahara Y, Ikeda H, Imai N, Sato E, Yamada T, Osako M, Ohnishi M, Harada N, Hishida T, Doki Y, Shiku H. Dose-dependent effects of NY-ESO-1 protein vaccine complexed with cholesteryl pullulan (CHP-NY-ESO-1) on immune responses and survival benefits of esophageal cancer patients. J Transl Med. 2013 Oct 5;11:246.
  7. Muraoka D, Nishikawa H, Noguchi T, Wang L, Harada N, Sato E, Luescher I, Nakayama E, Kato T, Shiku H. Establishment of animal models to analyze the kinetics and distribution of human tumor antigen-specific CD8? T cells. Vaccine. 2013 Apr 19;31(17):2110-8.
  8. Muraoka D, Kato T, Wang L, Maeda Y, Noguchi T, Harada N, Takeda K, Yagita H, Guillaume P, Luescher I, Old LJ, Shiku H, Nishikawa H. Peptide vaccine induces enhanced tumor growth associated with apoptosis induction in CD8+ T cells. J Immunol. 2010 Sep 15;185(6):3768-76.
  9. Harada N, Hoshiai K, Takahashi Y, Sakaguchi Y, Kuno T, Hishida T, Shiku H. Preclinical safety pharmacology study of a novel protein-based cancer vaccine CHP-NY-ESO-1. Kobe J Med Sci. 2008 May 23;54(1):E23-34.
  10. Nishikawa H, Kato T, Hirayama M, Orito Y, Sato E, Harada N, Gnjatic S, Old LJ, Shiku H. Regulatory T cell-resistant CD8+ T cells induced by glucocorticoid-induced tumor necrosis factor receptor signaling. Cancer Res. 2008 Jul 15;68(14):5948-54.